ChemicalBook > Product Catalog >Biochemical Engineering >Enzymes And Coenzymes drugs >Alteplase

Alteplase

Alteplase Suppliers list
Company Name: Hubei Jusheng Technology Co.,Ltd.
Tel: 86-18871470254
Email: linda@hubeijusheng.com
Products Intro: Product Name:Alteplase
CAS:105857-23-6
Purity:0.99 Package:5KG;1KG
Company Name: HENAN BON INDUSTRIAL CO.,LTD
Tel: 0371-55170695
Email: info@hnbon.com
Products Intro: CAS:105857-23-6
Purity:0.99 Package:25KG;5KG;1KG;500G
Company Name: Dideu Industries Group Limited
Tel: 029-88380327; 17691182729
Email: Service@dideu.com
Products Intro: Product Name:Alteplase USP/EP/BP
CAS:105857-23-6
Purity:99.9% Package:25kgs/Drum;200kgs/Drum Remarks:FDA GMP CEP Approved Manufacturer
Company Name: AFINE CHEMICALS LIMITED
Tel: 008657185134551
Email: info@afinechem.com
Products Intro: Product Name:ALTEPLASE
CAS:105857-23-6
Purity:98%+ Package:Standard or custom package Remarks:excellent quality and reliable supplier
Company Name: Hangzhou Huarong Pharm Co., Ltd.
Tel: +86-571-86758373
Email: sales@huarongpharm.com
Products Intro: Product Name:Alteplase
CAS:105857-23-6
Purity:0.99 Package:10MG,50MG,100MG,1G
Alteplase Basic information
Application in Ischemic Stroke
Product Name:Alteplase
Synonyms:Alteplase;Activase (tn);Alteplase (genetical recombination);Alteplase (genetical recombination) (jan);Alteplase (usp/inn);D02837;PlasMinogen activator (huMan tissue-type protein Moiety) (9CI);Alteplase USP/EP/BP
CAS:105857-23-6
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Alteplase Structure
Alteplase Chemical Properties
Safety Information
MSDS Information
Alteplase Usage And Synthesis
Application in Ischemic StrokeIn the therapy of Ischemic Stroke, Alteplase is initiated within 3 hours of symptom onset has been shown to reduce the ultimate disability due to ischemic stroke. A head CT scan must be obtained to rule out hemorrhage before beginning therapy.
It is administrated 0.9 mg/kg IV (maximum 90 mg) over 1 hour in selected patients within 3 hours of onset.
DescriptionAlteplase is a recombinant single-chain tissue plasminogen activator useful in the management of thrombosis in acute myocardial infarct. It reportedly causes no allergic reactions but requires intravenous infusion due to a short half-life. Alteplase is the only agent on the U.S. market indicated for the reduction of incidence of congestive heart failure following a heart attack.
OriginatorGenentech (USA)
UsesTissue-type plasminogen activator; fibrinolytic.
Brand nameActivase (Genentech);Actilyse.
General DescriptionAlteplase (Activase) is a tissue plasminogenactivator (t-PA) produced by rDNA technology. It is a single-chain glycoprotein protease consisting of 527 aminoacid residues. Native t-PA is isolated from a melanoma cellline. The single-chain molecule is susceptible to enzymaticdigestion to a two-chain molecule, in which the two chainsremain linked with a disulfide bond. Both forms of the nativet-PA are equipotent in fibrinolytic (and plasminogenactivating)properties. It is an extrinsic plasminogen activatorassociated with vascular endothelial tissue, whichpreferentially activates plasminogen bound to fibrin. Thefibrinolytic action of alteplase (t-PA) is confined to thrombi,with minimal systemic activation of plasminogen. It is producedcommercially by rDNA methods by inserting the alteplasegene (acquired from human melanoma cells) intoovarian cells of the Chinese hamster, serving as host cells.The melanoma-derived alteplase is immunologically andchemically identical with the uterine form. Alteplase is indicatedfor the intravenous management of acute myocardialinfarction.
Mechanism of actionAs a main endogenic promoter of fibrinolysis, t-PA binds with fibrin and, like urokinase, breaks Arg-560–Val-561 peptide bond in the fibrin-binded plasminogen molecule, thus turning it into an active plasmin molecule that breaks apart fibrin clots. Its action is localized in thrombotic regions, and thus the likelihood of systemic fibrinolysis originating during its use is much lower than that which can originate while using streptokinase and urokinase.
Clinical UseAlteplase (tPA) is a serine protease with a low affinity for free plasminogen but a very high affinity for the plasminogen bound to fibrin in a thrombus (fibrin-specific agent). Both streptokinase and urokinase lack this specificity (i.e., are nonspecific) and act on free plasminogen, inducing a generalized thrombolytic state. Alteplase also has a greater specificity for older clots compared with newer clots relative to streptokinase and urokinase. Alteplase was originally isolated from cultures of human melanoma cells but is now produced commercially using recombinant DNA technology.
Side effectsAlteplase is unmodified human tPA, whereas reteplase is human tPA that has had several specific amino acid sequences removed. At low doses, alteplase is quite selective for degrading fibrin without concomitant lysis of other proteins, such as fibrinogen. At the higher doses currently used therapeutically, however, alteplase activates free plasminogen to some extent and, therefore, can cause hemorrhage. Many of the therapeutic indications for the other thrombolytic agents also are indications for alteplase (i.e., myocardial infarction, massive pulmonary embolism, and acute ischemic stroke).
Alteplase Preparation Products And Raw materials
Tag:Alteplase(105857-23-6) Related Product Information
Hemocoagulase BATROXOBIN Clopidogrel Reteplase Ethyl isocyanoacetate COBALT(II) ACETYLACETONATE TERT-BUTYL ISOCYANIDE Cupric acetylacetonate Tris(2,4-pentanedionato)chroMiuM(III) Ferric acetylacetonate TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)DYSPROSIUM(III) COBALT ETHYLENE DIAMINE CHLORIDE Tosylmethyl isocyanide N-BUTYLISOCYANIDE Aluminum acetylacetonate DICHLORO(ETHYLENEDIAMINE)PLATINUM(II) 2,4-PENTANEDIONE, SILVER DERIVATIVE TRIS(2,2,6,6-TETRAMETHYL-3,5-HEPTANEDIONATO)EUROPIUM(III)